US Patent Issued to Seattle Children's Hospital on Nov. 3 for "Talen-based and CRISPR/Cas-based gene editing for Bruton's tyrosine kinase" (Washington Inventors)

ALEXANDRIA, Va., Nov. 3 -- United States Patent no. 12,781,227, issued on Nov. 3, was assigned to Seattle Children's Hospital (Seattle).

"Talen-based and CRISPR/Cas-based gene editing for Bruton's tyrosine kinase" was invented by David J. Rawlings (Seattle), Courtnee Clough (Edmonds, Wash.) and Iram F. Khan (Issaquah, Wash.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides improved genome editing compositions and methods for editing a human BTK gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of X-linked agammaglobulinemia (XLA)."

The patent was filed on April 26, 2019, under Application No. 17/050,7...